{"id":"NCT02174731","sponsor":"AstraZeneca","briefTitle":"Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.","officialTitle":"A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-01","primaryCompletion":"2018-09-26","completion":"2018-09-26","firstPosted":"2014-06-25","resultsPosted":"2019-12-16","lastUpdate":"2019-12-16"},"enrollment":2133,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Roxadustat","otherNames":[]},{"type":"DRUG","name":"Epoetin alfa","otherNames":[]}],"arms":[{"label":"Roxadustat","type":"EXPERIMENTAL"},{"label":"Epoetin alfa","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.","primaryOutcome":{"measure":"Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52","timeFrame":"Baseline (Day 1, Week 0), Week 28 to 52","effectByArm":[{"arm":"Roxadustat","deltaMin":0.77,"sd":0.041},{"arm":"Epoetin Alfa","deltaMin":0.68,"sd":0.04}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":188,"countries":["United States","Australia","Bulgaria","Canada","Czechia","Hungary","India","Mexico","Peru","Philippines","Poland","Russia","Slovakia","Spain","Sweden","Thailand","Ukraine","Vietnam"]},"refs":{"pmids":["38363466","36749544","36005278","35361724"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5740C00002&amp;attachmentIdentifier=1cab3812-b878-4cc4-9c31-d56a8992967c&amp;fileName=D5740C00002_redacted_CSP_from_PRS.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5740C00002&amp;attachmentIdentifier=4c981c0f-6734-4567-b362-92b2e86d7fdf&amp;fileName=D5740C00002-SAP-ed4_Redacted_(1).pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":604,"n":1048},"commonTop":["Diarrhoea","Hypertension","Headache","Nausea","Upper respiratory tract infection"]}}